July/August 2016 Newsletter 
Open to Accrual 
BTCRC-ESO14-012
Closed to Accrual 
Approved LOI 
BTCRC-BRE15-024
  • Advanced AR+ Triple Negative Breast Cancer
  • Sponsor-Investigator:
    Ruth O'Regan, MD
    University of Wisconsin Carbone Cancer Center
BTCRC-LUN15-017
  • Non-small cell lung cancer
  • Sponsor-Investigator:
    Lawrence Feldman, MD
    University of Illinois at Chicago
BTCRC-LUN15-029
  • Advanced non-small cell
    lung cancer
  • Sponsor-Investigator:
    Greg Durm, MD
    Indiana University Melvin and Bren Simon Cancer Center
Research Development
To Discuss Protocols: Contact Jessica Roy at jroy@bigtencrc.org or 317-634-5842, ext. 19

To Join a CTWG or Submit an LOI: Contact Anita Borek at
aborek@bigtencrc.org or  317-634-5842, ext. 48.

Support the BTCRC
Team up with the Big Ten Cancer Research Consortium. Together, we can make a big impact!

BTCRC Summit 2016
September 9-10, Indianapolis, Ind.
hosted by Indiana University Melvin and Bren Simon Cancer Center
Overview
This meeting will bring together members from Big Ten Cancer Research Consortium institutions, along with our colleagues from industry, to strengthen our collaboration and explore opportunities for novel therapeutic advances in clinical oncology.

Audience
  • Senior and junior faculty and fellows involved in clinical oncology research.
  • Basic scientists involved in drug discovery and translational research.
  • Cancer center leadership and administration.
  • Industry leadership and MSLs.
Agenda
Cost
  • There is no cost for registration.
  • Attendees are responsible for their own travel and accommodations. Meals and beverages are provided.
JW Marriott is offering a group rate of $169 per night for those who book before August 11. Book now (start 9/9; end 9/10).
BTCRC study completes accrual ahead of schedule 
The Big Ten Cancer Research Consortium's inaugural study, BTCRC-GU14-003, has reached its accrual goal well ahead of projections. The Phase Ib/II study of pembrolizumab and bevacizumab in combination for subjects with metastatic clear cell renal cell carcinoma, completed enrollment July 1, about six months ahead of schedule.
 
The study, led by sponsor-investigator Arkadiusz Dudek, MD, PhD, of the University of Illinois at Chicago, opened to accrual in March 2015. Ten BTCRC member cancer centers participated the study. Investigators presented Phase Ib results at the 2016 Genitourinary Cancers Symposium.
Breast, hepatocellular studies open  
BTCRC-BRE15-016: The University of Illinois at Chicago recently opened BTCRC-BRE15-016, a single arm Phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer. The study's sponsor-investigator is Oana Danciu, MD. See: Study Web Page * News Release * Video

BTCRC-GI13-002: Indiana University Melvin and Bren Simon Cancer Center has opened BTCRC-GI13-002, an open label randomized Phase I/II trial of MLN0128 compared to sorafenib in patients with advanced or metastatic hepatocellular carcinoma. The study's sponsor-investigator is Bert O'Neil, MD.
See: Study Web Page * News Release * Video 
Featured Member Profile 
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
"Participation in the consortium helps us all work together to mentor and develop the efforts of our junior faculty, and maximize the impact of our collective expertise."
 
Across the Consortium
Examples of initiative in the fight against cancer fill this month's Across the Consortium. Don't miss this action-packed edition!
Read more.
 
Want more news from Across the Consortium?